Deep vein thrombosis screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
==Value of screening==
==Value of screening==
There is no clear clinical value for screening, in-spite of identifying patients at increased risk of VTE. The following reason explains
In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains
* The strongest risk factor for VTE recurrence is the prior VTE event itself.
*The strongest risk factor for VTE recurrence is the prior VTE event itself.
* In VTE patients where the cause was unknown, after discontinuation of warfarin irrespective of the presence of inherited thrombophilia, are at high risk of recurrence.
*After discontinuation of warfarin in VTE patients, especially where the cause was unknown, There are at high risk of recurrence. irrespective of the presence of inherited thrombophilia.
*Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.
*Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.

Revision as of 14:39, 24 August 2011

Value of screening

In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains

  • The strongest risk factor for VTE recurrence is the prior VTE event itself.
  • After discontinuation of warfarin in VTE patients, especially where the cause was unknown, There are at high risk of recurrence. irrespective of the presence of inherited thrombophilia.
  • Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.